Patents by Inventor Manish Kumar Gupta
Manish Kumar Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11967984Abstract: Systems and methods for performing a Control Plane Triggered (CPT) Optical Protection Switching (OPS) policy are provided. A method, according to one implementation, includes performing a first route switching procedure for switching routes between an originating node and a terminating node. The first route switching procedure is configured to operate at a first priority level according to an Optical Protection Switching (OPS) policy. The method also includes performing a second route switching procedure for switching routes between the originating node and the terminating node. The second route switching procedure is configured to operate at a second priority level according to a second protection policy, wherein the second priority level is higher than the first priority level. Also, the method includes reverting back to a home path according to the first route switching procedure after one or more faults, defects, or degradations have been cleared from the home path.Type: GrantFiled: June 8, 2022Date of Patent: April 23, 2024Assignee: Ciena CorporationInventors: Sandeep Kumar Gupta, Vikas Chander, Manish Aggarwal, Parmita Kandiyal
-
Publication number: 20230364090Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.Type: ApplicationFiled: November 22, 2022Publication date: November 16, 2023Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkarni, Binuraj Krishnan Nair
-
Publication number: 20230263804Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.Type: ApplicationFiled: April 21, 2023Publication date: August 24, 2023Inventors: Manish Kumar Gupta, Kaustubh Tambwekar, Binuraj Krishnan Nair, Dilip J. Gole, Maristella Bernini, Sabine Inghelbrecht
-
Publication number: 20220339157Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib (Formula I) as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.Type: ApplicationFiled: May 4, 2022Publication date: October 27, 2022Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkarni, Binuraj Krishnan Nair
-
Publication number: 20220331307Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.Type: ApplicationFiled: February 3, 2022Publication date: October 20, 2022Inventors: Manish Kumar Gupta, Shripad Wasudeo Marathe, Kaustubh Ramesh Tambwekar, Shreedevi Velayudhan Nair
-
Publication number: 20220211713Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.Type: ApplicationFiled: March 29, 2022Publication date: July 7, 2022Inventors: Manish Kumar Gupta, Kaustubh Tambwekar, Binuraj Krishnan Nair, Dilip J. Gole, Maristella Bernini, Sabine Inghelbrecht
-
Publication number: 20210169888Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.Type: ApplicationFiled: February 11, 2021Publication date: June 10, 2021Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkarni, Binuraj Krishnan Nair
-
Patent number: 10778527Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.Type: GrantFiled: October 31, 2018Date of Patent: September 15, 2020Assignee: Oracle International CorporationInventors: Tarek Assali, Sridhar Karuturi, Jeffrey Alan Craig, Manish Kumar Gupta, Sameh Naguib
-
Publication number: 20200171036Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.Type: ApplicationFiled: December 10, 2019Publication date: June 4, 2020Inventors: Manish Kumar Gupta, Kaustubh Tambwekar, Binuraj Krishnan Nair, Dilip J. Gole, Maristella Bernini, Sabine Inghelbrecht
-
Publication number: 20200136911Abstract: An example system includes a service proxy controller and a number of service proxy workers. The service proxy controller is configured for providing routing policies for a telecommunications network core. The telecommunications network core includes network functions communicating using a service-based architecture. Each service proxy worker is configured for routing telecommunications network core messages between a respective subset of the network functions by consuming the routing policies from the service proxy controller and enforcing the routing policies from the service proxy controller. Each service proxy worker is configured for providing network status reports to the service proxy controller based on the telecommunications network core messages.Type: ApplicationFiled: October 31, 2018Publication date: April 30, 2020Inventors: Tarek Assali, Sridhar Karuturi, Jeffrey Alan Craig, Manish Kumar Gupta, Sameh Naguib
-
Publication number: 20190290650Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.Type: ApplicationFiled: January 18, 2017Publication date: September 26, 2019Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkami, Binuraj Krishnan Nair
-
Publication number: 20190282577Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.Type: ApplicationFiled: January 18, 2017Publication date: September 19, 2019Inventors: Manish Kumar Gupta, Parikshit Rameshrao Kulkarni, Binuraj Krishnan Nair
-
Publication number: 20180000810Abstract: The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.Type: ApplicationFiled: January 26, 2016Publication date: January 4, 2018Applicant: Janssen Pharmaceutica NVInventors: Manish Kumar Gupta, Shripad Wasudeo Marathe, Kaustubh Ramesh Tambwekar, Shreedevi Velayudhan NAIR
-
Publication number: 20170252344Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.Type: ApplicationFiled: May 23, 2017Publication date: September 7, 2017Inventors: Manish Kumar Gupta, Kaustubh Tambwekar, Binuraj Krishnan Nair, Dilip J. Gole, Maristella Bernini, Sabine Inghelbrecht
-
Publication number: 20160287594Abstract: Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate.Type: ApplicationFiled: April 6, 2016Publication date: October 6, 2016Inventors: Manish Kumar Gupta, Kaustubh Tambwekar, Binuraj Krishnan Nair, Dilip J. Gole, Maristella Bernini, Sabine Inghelbrecht
-
Patent number: 9215133Abstract: A policy and charging rules function (PCRF), generates a Diameter audit message concerning an application level Diameter session for which local resources are maintained by the PCRF. The PCRF includes, in the audit message, a fake parameter value. The PCRF sends the audit message with the fake parameter value to the OCS or the AF over an Sy or Rx interface. The PCRF receives a response to the audit message from the OCS or AF. The PCRF determines, based on the response, whether the application level session comprises and orphan session. The PCRF, in response to determining that the application level Diameter session comprises an orphan session frees the local resources maintained by the PCRF for the orphan session.Type: GrantFiled: February 20, 2013Date of Patent: December 15, 2015Assignee: Tekelec, Inc.Inventors: Uri Baniel, Tarek Abou-Assali, Manish Kumar Gupta, Sayan Chowdhury
-
Patent number: 8989056Abstract: The subject matter described herein includes systems, methods, and computer readable media for utilizing quota usage policy control in a Diameter-based communication network. An exemplary method includes, at a policy server, sending a request for quota usage information associated with a subscriber to an online charging system (OCS) node. The method further includes receiving the quota usage information from the OCS node, generating at least one policy and charging control (PCC) rule for modifying a quality of service (QoS) policy attribute associated with the subscriber based on the quota usage information, and communicating the at least one PCC rule to a Diameter network element.Type: GrantFiled: January 7, 2013Date of Patent: March 24, 2015Assignee: Tekelec, Inc.Inventors: Uri Baniel, Manish Kumar Gupta, Joseph Wonseok Lee
-
Publication number: 20140233368Abstract: A policy and charging rules function (PCRF), generates a Diameter audit message concerning an application level Diameter session for which local resources are maintained by the PCRF. The PCRF includes, in the audit message, a fake parameter value. The PCRF sends the audit message with the fake parameter value to the OCS or the AF over an Sy or Rx interface. The PCRF receives a response to the audit message from the OCS or AF. The PCRF determines, based on the response, whether the application level session comprises and orphan session. The PCRF, in response to determining that the application level Diameter session comprises an orphan session frees the local resources maintained by the PCRF for the orphan session.Type: ApplicationFiled: February 20, 2013Publication date: August 21, 2014Applicant: TEKELEC, INC.Inventors: Uri Baniel, Tarek Abou-Assali, Manish Kumar Gupta, Sayan Chowdhury